2026-06-14T14:33:43Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/71832024-11-28T17:25:02Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19609col_20.500.12105_16960

00925njm 22002777a 4500 dc Olmedo, Dionisio A author López-Pérez, José Luis author Del Olmo, Esther author Bedoya, Luis M author Sancho, Rocío author Alcamí, José author Muñoz, Eduardo author Feliciano, Arturo San author Gupta, Mahabir P author 2017-02-19 Twenty-eight neoflavonoids have been prepared and evaluated in vitro against HIV-1. Antiviral activity was assessed on MT-2 cells infected with viral clones carrying the luciferase reporter gene. Inhibition of HIV transcription and Tat function were tested on cells stably transfected with the HIV-LTR and Tat protein. Seven 4-phenylchromen-2-one derivatives showed HIV transcriptional inhibitory activity but only the phenylchrome-2-one 10 inhibited NF-κB and displayed anti-Tat activity simultaneously. Compounds 10, 14, and 25, inhibited HIV replication in both targets at concentrations <25 μM. The assays of these synthetic 4-phenylchromen-2-ones may aid in the investigation of some aspects of the anti-HIV activity of such compounds and could serve as a scaffold for designing better anti-HIV compounds, which may lead to a potential anti-HIV therapeutic drug. Molecules. 2017 Feb 19;22(2). pii: E321. 10.3390/molecules22020321 1420-3049 Molecules (Basel, Switzerland) 28218730 http://hdl.handle.net/20.500.12105/7183 4-phenyl-chromen-one AIDS NF-κB inhibition Tat protein Anti-HIV activity Neoflavonoids Neoflavonoids as Inhibitors of HIV-1 Replication by Targeting the Tat and NF-κB Pathways